Shares of Inovio Pharma Rally Following News of Positive Response Rate from Next-Gen HIV Vaccine
July 10, 2013 at 09:40 AM EDT
Inovio Pharmaceuticals, Inc. (NYSE: INO ) announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX^®-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA^® electroporation delivery device. The studies were conducted by the HIV Vaccine Trials
